vs
BioNTech SE（BNTX）与CareDx, Inc.（CDNA）财务数据对比。点击上方公司名可切换其他公司
BioNTech SE的季度营收约是CareDx, Inc.的12.9倍（$1.5B vs $117.7M），CareDx, Inc.净利率更高（2.4% vs -1.9%，领先4.3%）
BioNTech SE是总部位于德国美因茨的跨国生物技术企业，专注于免疫疗法及疫苗研发工作，核心研究方向覆盖肿瘤、传染性疾病等医疗领域，相关技术处于全球生物医药行业领先水平。
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
BNTX vs CDNA — 直观对比
营收规模更大
BNTX
是对方的12.9倍
$117.7M
净利率更高
CDNA
高出4.3%
-1.9%
损益表 — Q3 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $117.7M |
| 净利润 | $-28.7M | $2.8M |
| 毛利率 | — | — |
| 营业利润率 | -3.1% | — |
| 净利率 | -1.9% | 2.4% |
| 营收同比 | — | 39.0% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | — | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BNTXCDNA
| Q1 26 | — | $117.7M | ||
| Q4 25 | — | $108.4M | ||
| Q3 25 | $1.5B | $100.1M | ||
| Q2 25 | $260.8M | $86.7M | ||
| Q1 25 | — | $84.7M | ||
| Q4 24 | — | $86.6M | ||
| Q3 24 | $1.2B | $82.9M | ||
| Q2 24 | — | $92.3M |
净利润BNTXCDNA
| Q1 26 | — | $2.8M | ||
| Q4 25 | — | $-4.1M | ||
| Q3 25 | $-28.7M | $1.7M | ||
| Q2 25 | $-386.6M | $-8.6M | ||
| Q1 25 | — | $-10.4M | ||
| Q4 24 | — | $87.7M | ||
| Q3 24 | $198.1M | $-10.6M | ||
| Q2 24 | — | $-4.6M |
营业利润率BNTXCDNA
| Q1 26 | — | — | ||
| Q4 25 | — | -5.6% | ||
| Q3 25 | -3.1% | -0.2% | ||
| Q2 25 | -192.1% | -12.8% | ||
| Q1 25 | — | -15.8% | ||
| Q4 24 | — | 97.5% | ||
| Q3 24 | 0.8% | -16.6% | ||
| Q2 24 | — | -7.9% |
净利率BNTXCDNA
| Q1 26 | — | 2.4% | ||
| Q4 25 | — | -3.8% | ||
| Q3 25 | -1.9% | 1.7% | ||
| Q2 25 | -148.2% | -9.9% | ||
| Q1 25 | — | -12.2% | ||
| Q4 24 | — | 101.3% | ||
| Q3 24 | 15.9% | -12.8% | ||
| Q2 24 | — | -5.0% |
每股收益（稀释后）BNTXCDNA
| Q1 26 | — | $0.05 | ||
| Q4 25 | — | $-0.08 | ||
| Q3 25 | — | $0.03 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.19 | ||
| Q4 24 | — | $1.60 | ||
| Q3 24 | — | $-0.20 | ||
| Q2 24 | — | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $77.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | — |
| 总资产 | — | $411.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BNTXCDNA
| Q1 26 | — | $77.9M | ||
| Q4 25 | — | $177.2M | ||
| Q3 25 | — | $194.2M | ||
| Q2 25 | — | $186.3M | ||
| Q1 25 | — | $230.9M | ||
| Q4 24 | — | $260.7M | ||
| Q3 24 | — | $240.9M | ||
| Q2 24 | — | $228.9M |
总债务BNTXCDNA
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 |
股东权益BNTXCDNA
| Q1 26 | — | — | ||
| Q4 25 | — | $303.1M | ||
| Q3 25 | — | $311.1M | ||
| Q2 25 | — | $327.4M | ||
| Q1 25 | — | $379.3M | ||
| Q4 24 | — | $378.4M | ||
| Q3 24 | — | $273.2M | ||
| Q2 24 | — | $264.7M |
总资产BNTXCDNA
| Q1 26 | — | $411.1M | ||
| Q4 25 | — | $413.2M | ||
| Q3 25 | — | $432.3M | ||
| Q2 25 | — | $444.3M | ||
| Q1 25 | — | $489.6M | ||
| Q4 24 | — | $491.1M | ||
| Q3 24 | — | $477.0M | ||
| Q2 24 | — | $466.8M |
负债/权益比BNTXCDNA
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $4.3M |
| 自由现金流经营现金流 - 资本支出 | — | $514.0K |
| 自由现金流率自由现金流/营收 | — | 0.4% |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 1.54× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BNTXCDNA
| Q1 26 | — | $4.3M | ||
| Q4 25 | — | $21.4M | ||
| Q3 25 | — | $37.4M | ||
| Q2 25 | — | $9.9M | ||
| Q1 25 | — | $-26.6M | ||
| Q4 24 | — | $21.9M | ||
| Q3 24 | — | $12.5M | ||
| Q2 24 | — | $18.9M |
自由现金流BNTXCDNA
| Q1 26 | — | $514.0K | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
自由现金流率BNTXCDNA
| Q1 26 | — | 0.4% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金转化率BNTXCDNA
| Q1 26 | — | 1.54× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 22.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BNTX
暂无分部数据
CDNA
| Testing services revenue | $91.4M | 78% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
